Escin IA
Escin IA is a prodrug and its structure can be converted to desacylescin I by human intestinal bacteria and Lactobacillus brevis., desacylescin I as a biotransformation product shows potentially inhibitory effects on mouse tumor, and a potential candidate for anti tumor agents. Escin IA has anti-TNBC metastasis activity, and its action mechanisms involved inhibition of EMT process by down-regulating LOXL2 expression.
Inquire / Order:
manager@chemfaces.com
Technical Inquiries:
service@chemfaces.com
Tel:
+86-27-84237783
Fax:
+86-27-84254680
Address:
1 Building, No. 83, CheCheng Rd., Wuhan Economic and Technological Development Zone, Wuhan, Hubei 430056, PRC
Providing storage is as stated on the product vial and the vial is kept tightly sealed, the product can be stored for up to
24 months(2-8C).
Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20C. Generally, these will be useable for up to two weeks. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.
Need more advice on solubility, usage and handling? Please email to: service@chemfaces.com
The packaging of the product may have turned upside down during transportation, resulting in the natural compounds adhering to the neck or cap of the vial. take the vial out of its packaging and gently shake to let the compounds fall to the bottom of the vial. for liquid products, centrifuge at 200-500 RPM to gather the liquid at the bottom of the vial. try to avoid loss or contamination during handling.
Pharmaceuticals (Basel).2024, 17(4):442.
Applied Biological Chemistry 2021, 64(75)
Sci Rep.2018, 8:15059
Phytomedicine.2022, 100:154085.
Sci Rep.2018, 8(1):12970
Molecules.2021, 26(6):1635.
Front Pharmacol.2018, 9:236
Pharm Biomed Res2023, 9(3):173-182.
Int J Mol Sci.2024, 25(19):10660.
LWT-Food Sci Technol2020, 109163
Related and Featured Products
Oncotarget, 2016, 7(17):23684-99.
Escin Ia suppresses the metastasis of triple-negative breast cancer by inhibiting epithelial-mesenchymal transition via down-regulating LOXL2 expression[Pubmed:
27008697 ]
METHODS AND RESULTS:
The saponin fraction of Aesculus chinensis Bunge fruits (SFAC) could inhibit the invasion and migration of MDA-MB-231 cells. Among which, Escin IA showed more potent inhibition of the invasion than other five main saponin constituents. It selectively reduced the expression of LOXL2 mRNA and promoted the expression of E-cadherin mRNA, and prevented the EMT process of MDA-MB-231 cells and TNF-α/TGF-β-stimulated MCF-7 cells. Moreover, it reduced the LOXL2 level in MDA-MB-231 cells but not in MCF-7 cells. When MCF-7 cells were stimulated with TNF-α/TGF-β, transfected with LOXL2 or treated with hypoxia, Escin IA down-regulated the level of LOXL2 in MCF-7 cells. Meanwhile, Escin IA suppressed the EMT process in LOXL2-transfected or hypoxia-treated MCF-7 cells. Of interest, Escin IA did not alter the level of HIF-1α in hypoxia-induced MCF-7 cells.In TNBC xenograft mice, the metastasis and EMT of MDA-MB-231 cells were suppressed by Escin IA.
CONCLUSIONS:
In conclusion, Escin IA was the main active ingredient of SFAC for the anti-TNBC metastasis activity, and its action mechanisms involved inhibition of EMT process by down-regulating LOXL2 expression.
Beijing Da Xue Xue Bao. 2004,36(1):31-5.
Studies on the biotransformation of escin Ia by human intestinal bacteria and the anti-tumor activities of desacylescin I[Pubmed:
14970884]
To study Biotransformation of Escin IA by the crude enzymes of human intestinal bacteria and Lactobacillus brevis, determine the structures of biotransformation products and assay the inhibitory effect of desacylescin I on the tumor cell growth.
METHODS AND RESULTS:
The Escin IA was incubated with crude enzymes of human intestinal bacteria and Lactobacillus brevis in vitro, respectively. The biotransformation products were isolated and purified by the chromatographic methods and the structures were determined by the spectroscopic techniques.
Escin IA was converted into isoEscin IA, desacylescin I, 21beta-O-tigloylprotoaescigenin and protoaescigenin by crude enzymes of human intestinal bacteria and Lactobacillus brevis. Desacylescin I showed potentially inhibitory effects on tumor cell growth of mouse sarcoma-180, hepatic carcinoma H(22) and lung carcinoma in vivo.
CONCLUSIONS:
The results suggest that Escin IA was a prodrug and its structure can be converted by human intestinal bacteria and Lactobacillus brevis. Desacylescin I as a biotransformation product showed potentially inhibitory effects on mouse tumor, and a potential candidate for anti tumor agents.
